Cecilia Avram details the requirements for pharma companies post-Brexit and provides practical pointers on minimising the disruption to cross-border product availability as new rules come into force.
List view / Grid view
Filter the results
This article explores how implementing Radio Frequency Identification (RFID) technology could help NHS pathology services cope with the challenges of the COVID-19 pandemic.
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
The rapid evolution of the COVID-19 situation has created significant barriers to normal operations, from locking down borders to the imposition of restrictions on trade and export – not to mention a surge in demand for many common medicines. Each of these events in isolation can affect production and supply,…
The articles in this in-depth focus detail how Novartis prepared and adjusted their manufacturing and supply chain to minimise the impact of the COVID-19 pandemic and an exploration of what digitally enabled inventory processes can do to enhance FMD compliance.
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
Discover JRS PHARMA's industry leading manufacturing network for Microcrystalline Cellulose.
The International Air Cargo Association and Pharma.Aero will form a joint working group to provide air cargo guidance to the logistics industry for the transportation of COVID-19 vaccines.
Mike Owen details how supply chains have been disrupted by COVID-19 and why smart information management can offer a new source of renewed trust.
President Donald Trump has signed the 'Buy American' executive order, which is meant to reduce drug prices and protect the US from supply chain disruptions.
The UK government has written an open letter to medicine suppliers, outlining how supply can be maintained after the end of the Brexit transition period.
A survey has found that the biopharma industry is taking sustainability into their cold chain considerations more and more, with 66 percent saying it is very important.
According to a new report from the International Trade Committee, the UK's medicine supply chain was able to withstand the challenge of COVID-19, but must be optimised for a potential second wave of the virus.
The alliance between Chronicled and Deloitte intends to enhance security and efficiency in the pharma supply chain by bring to market new blockchain-powered solutions.